Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DWR4I7
|
|||
| Drug Name |
GBT021601
|
|||
| Synonyms |
Osivelotor; GBT-601; GBT021601; GBT-021601; 2417955-18-9; osivelotor [INN]; 2-hydroxy-6-({(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl}methoxy)benzaldehyde; 2-hydroxy-6-[[(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl]methoxy]benzaldehyde; SCHEMBL21957946; GTPL12856; UK749B4S16; example 8 [US20210047309]; HY-148788; CS-0641066; 2-hydroxy-6-{[(3S)-4-{[2-(2-hydroxyethyl)pyridin-3- yl]carbonyl}morpholin-3-yl]methoxy}benzaldehyde
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 2/3 | [1] | |
| Company |
Pfzer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N2O6
|
|||
| Canonical SMILES |
C1COCC(N1C(=O)C2=C(N=CC=C2)CCO)COC3=CC=CC(=C3C=O)O
|
|||
| InChI |
InChI=1S/C20H22N2O6/c23-9-6-17-15(3-2-7-21-17)20(26)22-8-10-27-12-14(22)13-28-19-5-1-4-18(25)16(19)11-24/h1-5,7,11,14,23,25H,6,8-10,12-13H2/t14-/m0/s1
|
|||
| InChIKey |
NIWBSQAKKNNWBT-AWEZNQCLSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05632354) An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial. U.S.National Institutes of Health. | |||
| REF 2 | GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.